Eupraxia Reports Positive 52-Week Phase 1b/2a Data for EP-104GI in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals announced positive 52-week data from the Phase 1b/2a RESOLVE trial evaluating EP-104GI for Eosinophilic Esophagitis (EoE). The highest dose group (Cohort 9) demonstrated significant durability, with 66% (2 of 3) of patients maintaining clinical remission at 52 weeks following a single administration. Across all cohorts followed for a full year (Cohorts 5-9), 64% (9 of 14) of patients remained in clinical remission at the 52-week mark. Histologic improvements were also noted, with Cohort 8b showing meaningful reductions in tissue inflammation and fibrosis at 36 weeks. Safety data remained favorable, with no treatment-related serious adverse events, no cases of oropharyngeal candidiasis, and no adrenal insufficiency reported across any of the 10 cohorts. The results support the potential for an annual dosing regimen. The Phase 2b portion of the RESOLVE trial is currently recruiting patients for 120mg and 160mg dose groups. Interim data from this randomized, placebo-controlled Phase 2b portion are expected in December 2026.